Press Releases Archives - Corvia Medical

Corvia Medical Announces Three-Year Clinical Trial Results Confirming Significant and Durable Benefits of the Corvia Atrial Shunt in Heart Failure Patients

44% reduction in total heart failure event rate and ongoing improvements in quality of life in responder group patients implanted with shunt TEWKSBURY, MA – October 25, 2024 – Corvia Medical, Inc, a company dedicated to transforming the treatment of heart failure, today announced impressive three-year results from its REDUCE LAP-HF II randomized clinical trial confirming […]

Corvia Medical’s Groundbreaking Study Affirms Long-Term Benefits of the Corvia Atrial Shunt for Heart Failure Patients

Responder group patients with the shunt experience a 50% lower heart failure event rate and a 46% improvement in quality of life over control group TEWKSBURY, MA – August 19, 2024 – Corvia Medical, Inc, a company dedicated to transforming the treatment of heart failure, today announced the publication in JACC-HF of two-year data from the […]

Newly Published Data in JAMA Cardiology Demonstrates Favorable Long-term Effects of the Corvia Atrial Shunt in Heart Failure Patients

Two years of echocardiographic data affirm positive effects of atrial shunt therapy on heart structure and function TEWKSBURY, MA – May 7, 2024 – Corvia Medical, Inc, a company dedicated to transforming the treatment of heart failure, today announced the publication in JAMA Cardiology of two-year echocardiographic data from its REDUCE LAP-HF II randomized clinical trial […]

Corvia’s RESPONDER-HF Confirmatory Trial Supported by RELIEVE-HF Data

Second major trial for atrial shunt therapy demonstrates importance of patient selection TEWKSBURY, MA – April 12, 2024 – Corvia Medical, Inc, a company dedicated to transforming the treatment of heart failure, welcomes the recent release of V-Wave’s RELIEVE-HF trial data supporting the evidence base around atrial shunt therapy, which is currently under study in the […]

Corvia Medical Releases Two-Year Clinical Trial Results Confirming Sustained Benefit and Safety of its Atrial Shunt in Heart Failure Patients

First-ever phase III randomized controlled trial of atrial shunt therapy shows continued promise TEWKSBURY, MA – May 22, 2023 – Corvia Medical, Inc, a company dedicated to transforming the treatment of heart failure, today announced two-year results from its REDUCE LAP-HF II randomized clinical trial confirming safety and sustained efficacy of the Corvia® Atrial Shunt […]

Corvia Medical Announces Randomization of First Patient in the RESPONDER-HF Confirmatory Trial

Corvia® Atrial Shunt has the potential to change the way heart failure is treated TEWKSBURY, MA – December 6, 2022 Corvia Medical, Inc., a company dedicated to transforming the treatment of heart failure (HF), announced the first patient has been randomized in RESPONDER-HF, a global confirmatory trial of the Corvia Atrial Shunt in heart failure […]

Corvia Medical Closes $54 Million Financing To Support Planned Confirmatory Trial Of The Corvia® Atrial Shunt

Existing investor syndicate supports atrial shunting as effective therapy for heart failure patients TEWKSBURY, MA – JUNE 9, 2022 Corvia Medical, Inc, a company dedicated to transforming the treatment of heart failure (HF), today announced the closing of a $54 million equity financing from its existing investor syndicate. Funds will be utilized to support a […]

REDUCE LAP-HF II Analyses show 50% of study patients demonstrated significant Clinical Benefit from the Corvia® Atrial Shunt

Landmark trial advances understanding of which HFpEF patients may benefit from atrial shunt therapy TEWKSBURY, MA – APRIL 1, 2022 Corvia Medical, Inc, a company dedicated to transforming the treatment of heart failure (HF), announced publication of analyses from its global, phase III REDUCE LAP-HF II randomized trial of heart failure patients with preserved (HFpEF) […]

Landmark REDUCE LAP-HF II Trial Demonstrates Clinical Benefit of Corvia® Atrial Shunt in Large Segment of Heart Failure Patients

REDUCE LAP-HF II study defines treatable HFpEF patient population for atrial shunt therapy TEWKSBURY, MA – FEBRUARY 1, 2022 Corvia Medical, Inc, a company dedicated to transforming the treatment of heart failure (HF), today announced results from its REDUCE LAP-HF II randomized clinical trial, investigating the safety and efficacy of the Corvia® Atrial Shunt in […]

Corvia Medical Completes Randomization in REDUCE LAP-HF II Pivotal Trial and Gains FDA Authorization to Provide Continued Access for the Corvia Atrial Shunt

Large randomized, sham-controlled trial evaluates interatrial shunting in a heart failure population currently without effective treatment TEWKSBURY, MA – November 17, 2020 — Corvia Medical, Inc., a company dedicated to transforming the treatment of heart failure (HF), today announced completion of randomization in its REDUCE LAP-HF II global, pivotal trial. The trial is evaluating the […]